Gene-edited T cells to treat diabetes inch closer to clinical trials – FierceBiotech

Scientists from the Seattle Children’s Research Institute and the Benaroya Research Institute have found a potential way to turn off the destructive autoimmune response in Type 1 diabetes—and it involves editing the genes of patients’ own T cells.

The team showed that by gene-editing CD4+ T cells to express a protein called FOXP3, they could turn the cells into cells with immunosuppressive properties, according to a new study published in the journal Science Translational Medicine. Taking a page from T cell receptor (TCR) technology that’s been explored as an anti-cancer treatment, the researchers further engineered the cells to be antigen-specific.

The engineered cells helped prevent Type 1 diabetes in mice, they reported at a recent meeting of the American Society of Gene and Cell Therapy.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm
Source…